THE WHAT? BASF and Orsted have signed a 25-year fixed price corporate power purchase agreement, under which BASF will offtake the output of 186 megawatts from Orsted’s planned wind farm in the North Sea. With its 25-year term, it’s said to be the longest CPPA for offshore wind ever announced.
THE DETAILS The new facility has a total installed capacity of 900 megawatts and is due to go into full commercial operation in 2025.
“In the common fight against climate change, it’s partners like BASF that will make the difference,” said Mads Nipper, CEO of Ørsted. “The chemical sector has a challenging path towards decarbonisation, but it will also make one of the biggest contributions. For this reason, countries like Germany must respond to the enormous demand for renewable electricity by urgently making more seabed available for offshore wind projects and by increasing its ambitions for deploying large-scale renewable energy sources such as offshore wind power. Offshore wind in the North Sea and the Baltic Sea is an abundant source of green electricity that can be unleashed through clearer and more ambitious policies. With our vision of a world that runs entirely on green energy, we aim to further accelerate the build out of renewable energy and support partners like BASF in realising their climate ambitions.”
THE WHY? Dr Martin Brudermüller, Chairman of the Board of Executive Directors of BASF SE, explains, “This supply agreement with Ørsted is another important step in securing additional renewable energy for BASF. BASF wants to reduce its CO2 emissions by 25 percent by 2030 compared with 2018. To achieve this ambitious goal, we will have to replace large amounts of fossil energy with renewable energy within the coming years. Ørsted can provide the required additional quantities through the construction of new wind farms to support us in our energy transformation.”
Aesthetic medicine products are developed and regulated to meet stringent safety and efficacy standards. They are typically administered by trained healthcare professionals such as dermatologists, plastic surgeons, and specialized nurses in clinical settings. These products aim to provide effective solutions for cosmetic enhancement, skin rejuvenation, and overall aesthetic improvement, contributing to both physical appearance and self-confidence.
Key categories of aesthetic medicine products include:
-
Injectables: This category includes products such as dermal fillers, botulinum toxins (e.g., Botox), and collagen stimulators. These injectables are used to smooth wrinkles, add volume, and improve facial contours.
-
Skin Rejuvenation Treatments: Products like chemical peels, microdermabrasion systems, and laser devices are used to improve skin texture, reduce pigmentation irregularities, and enhance overall skin tone.
-
Skincare Products: These include medical-grade cleansers, moisturizers, serums, and topical treatments containing active ingredients like retinoids, antioxidants, and growth factors. They are formulated to address specific skin concerns such as acne, aging, and hyperpigmentation.
-
Hair Restoration Products: Medical treatments and products designed to promote hair growth and treat conditions such as male and female pattern baldness.
-
Body Contouring and Fat Reduction: Devices and products used for non-surgical body sculpting, such as cryolipolysis (cool sculpting) devices and injectable lipolytics.
-
Cosmeceuticals: High-performance skincare products that bridge the gap between cosmetics and pharmaceuticals, often containing potent ingredients with proven clinical benefits.
-
Wound Care and Scar Management: Products like silicone sheets, gels, and advanced wound dressings used to improve healing and reduce the appearance of scars.
